Henderson Jane 4
4 · Apogee Therapeutics, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
Henderson Jane
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-03-02$68.27/sh−300$20,481→ 183,071 total - Sale
Common Stock
[F1][F3]2026-03-02$69.43/sh−300$20,829→ 182,771 total - Sale
Common Stock
[F1][F4]2026-03-02$70.45/sh−994$70,027→ 181,777 total - Sale
Common Stock
[F1][F5]2026-03-02$71.66/sh−406$29,094→ 181,371 total
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson|2026-03-04